Latest From Biotech Now

What’s New in RNAi Therapeutics?

87881842

At the 16th Annual BIO CEO & Investor Conference​, Monday morning’s therapeutic workshop, “Delivering the (RNAi) Goods,” featured a panel discussion moderated by Thomas Wei, senior research analyst at Jeffries LLC. The panel gave investors a peek into the novel approaches utilized by four leading companies in this area: Dicerna Pharmaceuticals, Arrowhead Research Corporation, Alnylam Pharmaceuticals, and Regulus Therapeutics. RNAi therapeutics, which include gene silencing, exon skipping, and mircroRNA therapy, are a promising area in the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14

Pops

The 16th Annual BIO CEO & Investor Conference opened with a fireside chat between Richard F. Pops, Chairman & Chief Executive Officer of Alkermes, and David Gluckman of Lazard. The candid discussion gave biotech CEOs a peek in to the story of Alkermes, yielding useful guidance on building a successful, agile company ready for a changing marketplace. Here are some of the highlights: Be world class in a specific area of science. “In our company, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Biotech Investors, Emerging Companies Bullish On 2014

Jim Greenwood

The 16th BIO CEO & Investor Conference is off to a great start. This event has truly grown into a must attend for emerging companies and investors. This year, we have more than 1,300 participants, including more than 850 investors. In addition, we have helped to set up more than 1,700 partnering meetings for participants over the course of the conference. Our world-class partnering system, and the opportunity to hear from key industry leaders, is Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

A New Addition to Pennsylvania Bio’s Leadership Team

ct-115x76

To effectively achieve our mission as the champion and advocate of biotechnology, BIO works with a broad network of organizations. Foremost among these relationships are the ones we possess with a broad network of state-based organizations known as the Council of State Bioscience Associations (CSBA). Pennsylvania Bio (PA Bio) has been a key ally to BIO and vocal advocate for state and federal public policy in support of the biotechnology industry since our inception. Just Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

FDA Week: For Biologics, A Name Isn’t Just A Name (Jim Greenwood op-ed)

Jim Greenwood

What is in a name? Names help make medicinal products more easily distinguishable by doctors, pharmacists and patients. When you are talking about biologics, complex medicines that are manufactured using living organisms, and biosimilars, medicines that are similar to, but not the same as, innovator biologics, naming is a significant consideration. As a pathway for biosimilars approval is implemented, a clear priority should be to craft a naming convention that both contributes to patient safety Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,